U.S. Healthcare Services Stock News

Oppenheimer Holdings Inc. reported first-quarter 2026 results, with revenue rising to US$445.1 million from US$367.83 million a year earlier, but swinging from net income of US$30.66 million to a net loss of US$20.58 million, and moving from basic earnings per share of US$2.93 to a basic loss of US$1.93. Despite this shift to a loss, the company also announced a quarterly dividend of US$0.20 per share payable on May 29, 2026, indicating continued cash returns to shareholders even as...

Wondering if Fox at around US$62.69 is priced for opportunity or already reflects the story? This piece walks through the key numbers to help you frame that question clearly. The stock has seen mixed recent returns, with a 1.3% decline over the last week, a 5.1% gain over the last 30 days, a 15.0% decline year to date and a 25.5% return over the last year, alongside longer term returns of 112.3% over three years and 72.6% over five years. Recent market interest has been shaped by ongoing...

If you are wondering whether American States Water at around US$76.84 is priced fairly or offering value, it helps to step back and look at what the recent share performance and fundamentals are signaling. Over the short term the stock is up 2.1% over the last week and is roughly flat over the past month with a 0.1% decline, while year to date it is up 6.3% and the 1 year return sits at a 1.8% decline. These moves come as investors continue to react to company specific developments and the...

Halozyme Therapeutics (NasdaqGS:HALO) has entered a new global collaboration with GSK to apply its ENHANZE technology to subcutaneous delivery of multiple oncology products. The agreement includes development of subcutaneous formulations for antibody drug conjugates, expanding ENHANZE into a new class of cancer therapies. The collaboration introduces additional potential royalty streams tied to future use of ENHANZE across GSK’s oncology portfolio. Halozyme Therapeutics, trading at $65.19,...

RPM International (RPM) drew fresh attention after reporting third quarter fiscal 2026 earnings and sales that exceeded expectations, alongside guidance regarding sales and adjusted EBIT. See our latest analysis for RPM International. The share price has eased back recently, with a 1 month share price return of 4.84% but a 90 day share price return decline of 13.30%, while the 1 year total shareholder return decline of 6.79% contrasts with a 3 year total shareholder return of 32.76%. This...

Investors may be wondering if Phibro Animal Health at around US$43.16 is still offering value after a strong run, or if the easy gains are behind it. The stock has pulled back 18.8% over the last week and 22.5% over the last month, yet it still shows a 15.7% gain year to date and a 96.6% return over the past year. These sharp moves are drawing attention back to what is already priced into Phibro Animal Health and how much of its story is reflected in the current share price. Ongoing interest...

Zai Lab (NasdaqGM:ZLAB) reported new clinical data from its global oncology and immunology pipeline, including intracranial response data for zoci in small cell lung cancer. The company is preparing to launch KarXT in China for schizophrenia in the next quarter. Management highlighted these pipeline and launch updates while also flagging near term revenue pressure. Zai Lab focuses on developing and commercializing medicines in oncology and immunology, as well as central nervous system...

If you are wondering whether Bruker stock is priced attractively or already reflects its prospects, the recent share moves make that question especially timely. The stock last closed at US$43.73, with returns of 19.1% over the past week and 19.3% over the past month, compared with an 8.5% gain over the past year and longer term returns over 3 and 5 years that have been negative. These shorter term gains come after a period where investors have been reassessing many life sciences and tools...

Digi International acquired Jolt Software and Particle Industries, reshaping its Internet of Things (IoT) offering. The company reports that these deals, combined with organic growth, have lifted annual recurring revenue (ARR) by 50%. Management highlights strong cash flow as a key support for integrating these acquisitions into the existing business. Digi International (NasdaqGS:DGII) is drawing fresh attention as it leans harder into IoT platforms and recurring software revenue. The stock...

Main Street Capital (MAIN) has wrapped up FY 2025 with fourth quarter revenue of US$145.5 million and basic EPS of US$1.46. This sets the tone for a year in which trailing twelve month revenue reached US$566.4 million and EPS was US$5.52. Over recent periods, the company has reported quarterly revenue ranging between US$137.0 million and US$145.5 million, while basic EPS has moved between US$1.31 and US$1.46. Trailing net income for the year was US$493.4 million, as investors weigh those...

In the first quarter ended March 31, 2026, Revolve Group, Inc. reported sales of US$342.88 million, net income of US$14.35 million, and diluted earnings per share from continuing operations of US$0.20, all higher than a year earlier. This past-quarter improvement in both revenue and profitability gives investors fresh data to reassess how Revolve’s growth investments may be translating into earnings power. With first-quarter revenue and net income both higher year over year, we’ll now...

D-Market Elektronik Hizmetler ve Ticaret A.S. recently released its first-quarter 2026 results, reporting sales of TRY 23,136.56 million compared with TRY 18,827.87 million a year earlier, alongside a net loss of TRY 991.97 million versus TRY 464.69 million previously. The combination of strong top-line expansion and a larger loss underlines how D-Market’s growth investments and cost structure are still weighing on profitability. Next, we’ll examine how this strong revenue growth but wider...

Gran Tierra Energy (NYSEAM:GTE) has wrapped up FY 2025 with fourth quarter revenue of US$132.6 million and a basic EPS loss of US$3.99, alongside a full year trailing revenue base of US$596.7 million and a trailing basic EPS loss of US$5.45. Over recent periods, the company has seen quarterly revenue range from US$147.0 million to US$170.5 million. Basic EPS has moved between a small profit of US$0.04 in late 2024 and losses including US$0.54 in the first quarter of 2025, setting up an...

Wondering if Matador Resources at around US$55.57 is offering solid value or asking too much for its growth story? This article walks through the key signals to help you judge whether the current price looks appealing. The stock has pulled back with a 12.4% decline over the last 7 days and a 13.8% decline over the last 30 days, even though the year to date return sits at 28.2% and the 1 year return at 35.3%. Recent coverage has focused on Matador Resources in the context of broader energy...

NI Holdings (NODK) just closed out FY 2025 with Q4 total revenue of US$61.0 million and a basic EPS loss of US$0.15, alongside a net loss of US$3.2 million, putting margins firmly under pressure. Over recent quarters, total revenue has moved from US$73.9 million in Q4 2024 to US$71.4 million in Q1 2025 and US$76.1 million in Q2 2025 before landing at US$61.0 million in Q4 2025, while EPS has swung from a profit of US$0.47 in Q4 2024 to a loss of US$0.57 in Q2 2025 and a loss of US$0.15 in the...

Sharplink (NasdaqCM:SBET) has wrapped up FY 2025 with Q4 revenue of US$15.8 million and basic EPS of a US$3.51 loss, against a backdrop of trailing twelve month revenue of US$28.1 million and basic EPS of a US$7.37 loss. Over recent quarters, the company has seen quarterly revenue move from US$0.7 million in Q1 2025 to US$10.8 million in Q3 2025 and then US$15.8 million in Q4 2025, while EPS shifted from a US$1.73 loss in Q1 to EPS of US$0.70 in Q3 and back to a US$3.51 loss in Q4. This puts...

Investors may be wondering whether Huron Consulting Group at around US$124.78 is starting to look attractive, or if the stock price still reflects too much optimism. The share price has slipped by about 4.5% over the past week and 5.2% over the past month, adding to a 27.1% decline year to date and an 18.0% return over the last year. This contrasts with the 3-year and 5-year returns, which stand at 54.7% and 126.4% respectively. These recent moves sit against a backdrop of ongoing interest...

Investors may be wondering if Capricor Therapeutics at around US$33.94 is still offering value after a strong run, or if most of the opportunity is already reflected in the price. The stock has returned 1.1% over the last week, 6.2% over the past month and 19.9% year to date, with a very large 1 year return of 386.9% and around 7x over 3 years. This naturally raises questions about the current balance of risk and reward. Recent coverage has focused on Capricor Therapeutics because of its...

Wondering if USA Rare Earth at around US$26.38 is still offering value after a strong run, or if you are late to the party? This breakdown focuses squarely on what the current price might be implying. The stock has recent returns of 1.6% over 7 days, 80.2% over 30 days, 86.4% year to date and 163.8% over the past year, which will naturally raise questions about how much optimism is already priced in. Recent coverage of USA Rare Earth has highlighted growing investor attention on rare earth...

If you are wondering whether Flutter Entertainment's current share price really reflects what you are getting for your money, this article breaks down how the stock looks on several valuation yardsticks. After closing at US$101.20, the stock has seen a 6.2% decline over the past week, a 2.3% decline over the last month, and a 53.6% decline year to date. It has also declined 58.0% over the last year and 49.0% and 43.1% over the past 3 and 5 years respectively. Recent coverage has focused on...

Esperion Therapeutics (ESPR) closed out FY 2025 with fourth quarter revenue of US$168.4 million and basic EPS of US$0.26, alongside trailing twelve month revenue of US$403.1 million and a basic EPS loss of US$0.11. Over recent quarters the company has seen revenue move from US$69.1 million in Q4 2024 to US$168.4 million in Q4 2025, while quarterly EPS shifted from a loss of US$0.11 in Q4 2024 to EPS of US$0.26 in Q4 2025. This sets up a results season in which investors will be weighing how...

If you are wondering whether Gilat Satellite Networks at around US$18.84 is priced for opportunity or disappointment, the starting point is to understand what the current valuation is really implying. The stock has posted returns of 2.1% over the last 7 days and 2.2% over the last 30 days, with year to date returns of 40.5% and a 1 year return of 189.0%, alongside a 3 year return of 243.2% and a 5 year return of 119.8%. Recent news flow around Gilat Satellite Networks has focused on its...

Wondering if Aptiv's current share price reflects its true worth, or if the recent swings are masking a clearer story about value. Aptiv closed at US$57.11, with returns of a 5.2% decline over 7 days, a 1.9% decline over 30 days, a 27.2% decline year to date, but a 10.3% gain over the past year, which can leave the stock looking quite different depending on the time frame you focus on. Those mixed returns sit against a backdrop of ongoing attention on Aptiv as an auto components supplier, as...

Geospace Technologies (GEOS) opened Q1 2026 with revenue of US$25.6 million and a basic EPS loss of US$0.76, alongside a trailing twelve month basic EPS loss of US$2.17 on revenue of US$99.2 million. Over recent quarters the company has reported revenue between US$18.0 million and US$37.2 million, while EPS has ranged from a profit of US$0.66 per share in Q1 2025 to several loss-making quarters since. For investors, that mix of fluctuating topline and persistent losses keeps the attention on...